Markets

Insider Trading

Hedge Funds

Retirement

Opinion

5 Best Healthcare Stocks to Buy Under $20

In this article, we will be taking a look at the 5 best healthcare stocks to buy under $20. To read our detailed analysis of the healthcare sector, you can go directly to see the 10 Best Healthcare Stocks to Buy Under $20.

5. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Number of Hedge Fund Holders: 33

Share Price: $17.2

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biotechnology company. It offers medicines for central nervous system disorders and rare diseases.

An Overweight rating and $37 price target were maintained on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on April 10 by Cantor Fitzgerald analysts.

We saw 33 hedge funds long ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in the fourth quarter, with a total stake value of $1.9 billion.

Follow Acadia Pharmaceuticals Inc (NASDAQ:ACAD)

4. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Number of Hedge Fund Holders: 34

Share Price: $12.3

Piper Sandler analysts hold an Overweight rating and $19 price target on Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) as of March 14.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a biotech company based in San Carlos, California. It develops cell therapies using autologous tumor infiltrating lymphocytes to treat metastatic melanoma and other solid tumor cancers.

In total, 34 hedge funds were long Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) in the fourth quarter, with a total stake value of $554.9 million.

Aristotle Atlantic Partners, LLC made the following comments about Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) in its third quarter 2023 investor letter:

“We sold Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) following uncertainty which arose from the company canceling out of two investor events. Iovance is in the late stages of FDA review on their lead candidate Lifileucel in advanced melanoma. These cancellations could stem from issues with site inspections which tend to take place later in the review cycle. The company has not commented on why it canceled these investor events, and we do not think this bodes well for the prospects of a straightforward approval with a clean, positive label for the company.”

Follow Iovance Biotherapeutics Inc. (NASDAQ:IOVA)

3. Elanco Animal Health Incorporated (NYSE:ELAN)

Number of Hedge Fund Holders: 35

Share Price: $14.3

Elanco Animal Health Incorporated (NYSE:ELAN) was seen in the portfolios of 35 hedge funds in the fourth quarter, with a total stake value of $844.4 million.

Based in Greenfield, Indiana, Elanco Animal Health Incorporated (NYSE:ELAN) is an animal health company. It offers pet health and disease prevention products such as parasiticides and vaccines.

As of February 27, Morgan Stanley analysts hold an Overweight rating and a $17 price target on Elanco Animal Health Incorporated (NYSE:ELAN).

Follow Elanco Animal Health Inc (NYSE:ELAN)

2. Viatris Inc. (NASDAQ:VTRS)

Number of Hedge Fund Holders: 43

Share Price: $11.5

Viatris Inc. (NASDAQ:VTRS) is a pharmaceutical company. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients.

A total of 43 hedge funds were long Viatris Inc. (NASDAQ:VTRS) in the fourth quarter, with a total stake value of $1.2 billion.

Piper Sandler analysts maintain a Neutral rating and $13 price target on Viatris Inc. (NASDAQ:VTRS) as of March 28.

Greenlight Capital said the following about Viatris Inc. (NASDAQ:VTRS) in its fourth-quarter 2023 investor letter:

We established medium-sized positions in Alight (ALIT) and Viatris Inc. (NASDAQ:VTRS), and a small position in Syensqo (Belgium: SYENS). VTRS is a manufacturer of generic and off-patent branded drugs. The company was created in 2020 after a merger between Mylan and a division of Pfizer. We previously invested in Mylan, but sold five years ago due to concerns around management’s ability to deliver on promises, as well as deterioration in the generic industry. Those concerns were well-founded, as the shares proceeded to decline by more than 60% after we exited. After a recent management change, we decided to take another look and found that after years of sharp declines, generic drug pricing has stabilized and competition has been diminished. The company’s revenue and cash flow are now growing, and we expect this improvement to accelerate. VTRS’ new management team has simplified its drug portfolio via various divestitures and has committed to returning 50% of free cash flow to shareholders through “aggressive” share buybacks, implying a double-digit capital return based on our estimates. We acquired our shares at an average price of $10.63, or just 4.0x 2024 consensus earnings. VTRS shares ended the quarter at $10.83.”

Follow Viatris Inc (NASDAQ:VTRS)

1. Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Number of Hedge Fund Holders: 50

Share Price: $13.3

On February 12, Piper Sandler analysts placed an Overweight rating and $19 price target on Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Teva Pharmaceutical Industries Limited (NYSE:TEVA) had 50 hedge funds long its stock in the fourth quarter, with a total stake value of $1.5 billion.

Based in Tel Aviv, Israel, Teva Pharmaceutical Industries Limited (NYSE:TEVA) is a pharmaceutical company. It offers generic medicines, specialty medicines, and biopharmaceutical products.

Sound Shore Management mentioned Teva Pharmaceutical Industries Limited (NYSE:TEVA) in its third-quarter 2023 investor letter:

“Away from power, drug maker Teva Pharmaceutical Industries Limited (NYSE:TEVA), a new holding, also performed well during the quarter. Teva develops, manufactures and markets generic and specialty drugs focused on neurological and respiratory diseases, as well as oncology. Following a period of poor capital allocation decisions in prior years, we were able to invest at a very attractive valuation. We now believe management has positioned the company for renewed growth, driven by its most promising branded drug pipeline in years. The investment is off to a good start and the stock gained after second quarter results topped consensus.”

Follow Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

See also Insiders Are Dumping These 10 Healthcare Stocks and 11 Best Healthcare ETFs To Buy Now.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.